Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults

NCT05458232 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-11-04

No results posted yet for this study

Summary

This study will be the first demonstration of the utility and feasibility of Phosphodiesterase Type 5 inhibitor as an effective pharmacological therapy for improving anabolic resistant states.

Conditions

Interventions

DRUG

Tadalafil 5mg

Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Eligibility

Min Age
60 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-20
Primary Completion
2023-01-20
Completion
2023-01-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05458232 on ClinicalTrials.gov